(part 1 only) have a histologically or cytologically confirmed diagnosis of advanced solid tumor that has relapsed or is refractory to standard curative or palliative therapy or has a contraindication to standard therapy.

(part 2 only) have histologically or cytologically confirmed diagnosis of stage iiib or iv nsclc and have received 1 or 2 lines of prior chemotherapy or targeted therapy for stage iiib or iv nsclc (second- or third-line).

have measurable disease per response evaluation criteria in solid tumors (recist) version 1.1.

eastern cooperative oncology group (ecog) performance status of 0 to 1

have adequate bone marrow reserve, liver function, and renal function

have received prior platinum therapy in the past 3 months

have received prior cisplatin and gemcitabine concomitantly within the last 6 months or are refractory to cisplatin and gemcitabine.

unresolved toxicity from prior radiation, chemotherapy, or other targeted treatment, including investigational treatment

pregnant or breast feeding